Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Espha to Launch Zetia AG in June
February 4, 2020
- Astellas’ 9-Month Sales Dip 1.6%, but in Positive Territory If Forex Impact Excluded
February 3, 2020
- Daiichi Sankyo Enjoys 7.7% Rise in April-December Sales; Enhertu Off to Solid Start
February 3, 2020
- Opdivo Sales Drop 4.7% in April-December, but Ono Secures Higher Profits
February 3, 2020
- CureApp to File Hypertension Treatment App as Early as 2021, PIII Trial Now Underway
February 3, 2020
- Eisai's April-December Operating Profit Surges 28.4% on Lenvima, Guidance Lifted
February 3, 2020
- Asahi Kasei Expands License for iPS Cell-Derived Cartilage Products to Osteoarthritis, Meniscus Injury
February 3, 2020
- Sandoz Completes Aspen Japan Buyout
February 3, 2020
- ViiV Rolls Out HIV Doublet Dovato in Japan
February 3, 2020
- Sumitomo Dainippon’s April-December Sales Up 2.9% as Diabetes Meds Counter Off-Patent Dip
January 31, 2020
- Chugai Ups Core EPS CAGR Target to “Around 30%”: 3-Year Biz Plan
January 31, 2020
- Chugai’s 2019 Earnings Renews Record for Third Year on Hemlibra, Tecentriq
January 31, 2020
- Sumitomo Dainippon Starts Japan PI for AI-Designed Drug Candidate
January 31, 2020
- Evrenzo Filed for Anemia in Non-Dialysis CKD Patients in Japan: Astellas/FibroGen
January 31, 2020
- AstraZeneca Taps AI Chatbot to Answer Inquiries from Patient, Healthcare Providers
January 31, 2020
- Takeda Submits Cabozantinib in Japan for HCC, RCC OK Expected Soon
January 30, 2020
- Eisai Pairs Up with US Biotech on Liquid Biopsy-Based Genomic Profiling
January 30, 2020
- Novo’s Hemophilia A Med Esperoct Hits Shelves in Japan
January 30, 2020
- Chugai, UK Institutes Reach Settlement over Actemra Royalty Row
January 29, 2020
- Daiichi Sankyo’s DS-8201 Hits Primary Target in PII Gastric Cancer Trial
January 28, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…